Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is there any role for new prognostic markers in breast cancer?

× No keyword cloud information.

11 in total

1. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors: Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808

2. Stat5: from breast development to cancer prognosis, prediction, and progression.

Authors: David Tweardy; Jenny C Chang
Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544

3. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis.

Authors: Amir Sonnenblick; Anat Shriki; E Galun; Jonathan H Axelrod; Hagit Daum; Yakir Rottenberg; Tamar Hamburger; Bela Mali; Tamar Peretz
Journal: Clin Transl Oncol Date: 2012-03 Impact factor: 3.405

4. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Authors: J Albanell; A González; M Ruiz-Borrego; E Alba; J A García-Saenz; J M Corominas; O Burgues; V Furio; A Rojo; J Palacios; B Bermejo; M Martínez-García; M L Limon; A S Muñoz; M Martín; I Tusquets; F Rojo; R Colomer; I Faull; A Lluch
Journal: Ann Oncol Date: 2011-06-06 Impact factor: 32.976

5. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.

Authors: H Yamashita; M Nishio; Y Ando; Z Zhang; M Hamaguchi; K Mita; S Kobayashi; Y Fujii; H Iwase
Journal: Endocr Relat Cancer Date: 2006-09 Impact factor: 5.678

6. Molecular portraits of human breast tumours.

Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal: Nature Date: 2000-08-17 Impact factor: 49.962

7. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.

Authors: Marisa Dolled-Filhart; Robert L Camp; Diane P Kowalski; Bradley L Smith; David L Rimm
Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531

8. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors: A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal: Ann Oncol Date: 2011-06-27 Impact factor: 32.976

Review 9. Deconstructing the molecular portraits of breast cancer.

Authors: Aleix Prat; Charles M Perou
Journal: Mol Oncol Date: 2010-11-24 Impact factor: 6.603

10. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors: A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal: Ann Oncol Date: 2009-06-17 Impact factor: 32.976